Description
a presentation on BIOCON
Industry: Biotechnology ? Founders, Chairman &M.D: Kiran Mazumdar Shaw ? Founded:1978 ? Headquarters: Bangalore ? Employees:6000(approx)
?
SHAREHOLDERS
Employees Trust Promoters Public
PERCENTAGE
13% 65% 22%
1978:-Indian’s #1 Biotech company with a global biotech ranking of 16 ? 1979:-Global leadership in specialty enzymes ? 1989:-Globally unique fermentation profile ? 1994:-SYNGENE-India’s first research company ? 2003:- India’s first and largest Antibody Facility-Clinigene
?
Revenue:-240 million US$(2011-12) ? Profit:-39 million US$(2011-12) ? Traded as BIOCON in NSE ? Face Value: Rs 5 ? Market Cap:-9222 crore ? EPS:- Rs. 15.43 ? P/E Ratio:29.83
?
? ? ? ? ?
Biotechnology has transformed many parts of the chemical industry, agriculture and medicine. The consumption of biotech products in India was expected to quadruple within a decade. The human and animal segment of the industry alone was growing by at least 20%. From 2009, Indian Biotech Industry contributes to 3.5% of the global biotech industry. In India 800 Companies were operating in all sectors of biotechnology, but only 25 were working in the modern biotech sectors.
?Government is implementing a national Biotechnology Development Strategy (NBDS) and establishing a national Biotechnology Regulatory Authority (NBRA) . ?100% FDI in biotechnology sector. ?Special tax benefits.
THANK YOU
doc_882131768.pptx
a presentation on BIOCON
Industry: Biotechnology ? Founders, Chairman &M.D: Kiran Mazumdar Shaw ? Founded:1978 ? Headquarters: Bangalore ? Employees:6000(approx)
?
SHAREHOLDERS
Employees Trust Promoters Public
PERCENTAGE
13% 65% 22%
1978:-Indian’s #1 Biotech company with a global biotech ranking of 16 ? 1979:-Global leadership in specialty enzymes ? 1989:-Globally unique fermentation profile ? 1994:-SYNGENE-India’s first research company ? 2003:- India’s first and largest Antibody Facility-Clinigene
?
Revenue:-240 million US$(2011-12) ? Profit:-39 million US$(2011-12) ? Traded as BIOCON in NSE ? Face Value: Rs 5 ? Market Cap:-9222 crore ? EPS:- Rs. 15.43 ? P/E Ratio:29.83
?
? ? ? ? ?
Biotechnology has transformed many parts of the chemical industry, agriculture and medicine. The consumption of biotech products in India was expected to quadruple within a decade. The human and animal segment of the industry alone was growing by at least 20%. From 2009, Indian Biotech Industry contributes to 3.5% of the global biotech industry. In India 800 Companies were operating in all sectors of biotechnology, but only 25 were working in the modern biotech sectors.
?Government is implementing a national Biotechnology Development Strategy (NBDS) and establishing a national Biotechnology Regulatory Authority (NBRA) . ?100% FDI in biotechnology sector. ?Special tax benefits.
THANK YOU
doc_882131768.pptx